1-6 of 6
Daniel H. Albert
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Selective Inhibition of the Second Bromodomain of BET Family Proteins Results in Robust Antitumor Activity in Preclinical Models of Acute Myeloid Leukemia

Lu Zhang, Tianyu Cai, Xiaoyu Lin, Xiaoli Huang, Mai H. Bui, Joshua P. Plotnik, Richard J. Bellin, Emily J. Faivre, Vinitha M. Kuruvilla, Lloyd T. Lam, Xin Lu, Zheng Zha, Weiguo Feng, Paul Hessler, Tamar Uziel, Qi Zhang, Antonio Cavazos, Lina Han, Debra C. Ferguson, Gaurav Mehta, Sriram S. Shanmugavelandy, Terrance J. Magoc, Jenny Rowe, Neal C. Goodwin, Kathleen A. Dorritie, Michael Boyiadzis, Daniel H. Albert, Keith F. McDaniel, Warren M. Kati, Marina Konopleva, Yu Shen
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (10): 1809–1819.
https://doi.org/10.1158/1535-7163.MCT-21-0029
Published: 01 October 2021
View article titled, Selective Inhibition of the Second Bromodomain of BET Family Proteins Results in Robust Antitumor Activity in Preclinical Models of Acute Myeloid Leukemia
Open the PDF for Selective Inhibition of the Second Bromodomain of BET Family Proteins Results in Robust Antitumor Activity in Preclinical Models of Acute Myeloid Leukemia in another window
Includes: Supplementary data
Journal Articles

Vulnerability of Small-Cell Lung Cancer to Apoptosis Induced by the Combination of BET Bromodomain Proteins and BCL2 Inhibitors

Lloyd T. Lam, Xiaoyu Lin, Emily J. Faivre, Ziping Yang, Xiaoli Huang, Denise M. Wilcox, Richard J. Bellin, Sha Jin, Stephen K. Tahir, Michael Mitten, Terry Magoc, Anahita Bhathena, Warren M. Kati, Daniel H. Albert, Yu Shen, Tamar Uziel
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2017) 16 (8): 1511–1520.
https://doi.org/10.1158/1535-7163.MCT-16-0459
Published: 02 August 2017
View article titled, Vulnerability of Small-Cell Lung Cancer to Apoptosis Induced by the Combination of BET Bromodomain Proteins and BCL2 Inhibitors
Open the PDF for Vulnerability of Small-Cell Lung Cancer to Apoptosis Induced by the Combination of BET Bromodomain Proteins and BCL2 Inhibitors in another window
Includes: Supplementary data
Journal Articles

HEXIM1 as a Robust Pharmacodynamic Marker for Monitoring Target Engagement of BET Family Bromodomain Inhibitors in Tumors and Surrogate Tissues

Xiaoyu Lin, Xiaoli Huang, Tamar Uziel, Paul Hessler, Daniel H. Albert, Lisa A. Roberts-Rapp, Keith F. McDaniel, Warren M. Kati, Yu Shen
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2017) 16 (2): 388–396.
https://doi.org/10.1158/1535-7163.MCT-16-0475
Published: 02 February 2017
View article titled, <em>HEXIM1</em> as a Robust Pharmacodynamic Marker for Monitoring Target Engagement of BET Family Bromodomain Inhibitors in Tumors and Surrogate Tissues
Open the PDF for <em>HEXIM1</em> as a Robust Pharmacodynamic Marker for Monitoring Target Engagement of BET Family Bromodomain Inhibitors in Tumors and Surrogate Tissues in another window
Includes: Supplementary data
Journal Articles

Abstract C202: Discovery and initial characterization of the clinical compound ABT-348, a potent inhibitor of the VEGF, PDGF, and Aurora kinase families.

Michael L. Curtin, Robin Heyman, Robin R. Frey, Niru B. Soni, Patick A. Marcotte, Lori J. Pease, Keith B. Glaser, Terrance J. Magoc, Paul Tapang, Daniel H. Albert, Donald J. Osterling, Amanda M. Olson, Jennifer J. Bouska, Zhiwen Guan, Ruth L. Martin, Kent D. Stewart, Chris Tse, Steven K. Davidsen, Michael R. Michaelides
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): C202.
https://doi.org/10.1158/1535-7163.TARG-11-C202
Published: 12 November 2011
View article titled, Abstract C202: Discovery and initial characterization of the clinical compound ABT-348, a potent inhibitor of the VEGF, PDGF, and Aurora kinase families.
Journal Articles

Abstract A239: Preclinical characterization of ABT-348, a kinase inhibitor targeting the Aurora, VEGFR/PDGFR, and SRC kinase families.

Keith B. Glaser, Junling Li, Patrick A. Marcotte, Terrance J. Magoc, Jun Guo, David R. Reuter, Paul Tapang, Ru-Qi Wei, Lori J. Pease, Mai H. Bui, Zehan Chen, Robin R. Frey, Eric F. Johnson, Donald J. Osterling, Amanda M. Olson, Jennifer J. Bouska, Michael L. Curtin, Cherrie K. Donawho, Michael R. Michaelides, Chris Tse, Steven K. Davidsen, Daniel H. Albert
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): A239.
https://doi.org/10.1158/1535-7163.TARG-11-A239
Published: 12 November 2011
View article titled, Abstract A239: Preclinical characterization of ABT-348, a kinase inhibitor targeting the Aurora, VEGFR/PDGFR, and SRC kinase families.
Journal Articles

Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor

Daniel H. Albert, Paul Tapang, Terrance J. Magoc, Lori J. Pease, David R. Reuter, Ru-Qi Wei, Junling Li, Jun Guo, Peter F. Bousquet, Nayereh S. Ghoreishi-Haack, Baole Wang, Gail T. Bukofzer, Yi-Chun Wang, Jason A. Stavropoulos, Kresna Hartandi, Amanda L. Niquette, Nirupama Soni, Eric F. Johnson, J. Owen McCall, Jennifer J. Bouska, Yanping Luo, Cherrie K. Donawho, Yujia Dai, Patrick A. Marcotte, Keith B. Glaser, Michael R. Michaelides, Steven K. Davidsen
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2006) 5 (4): 995–1006.
https://doi.org/10.1158/1535-7163.MCT-05-0410
Published: 28 April 2006
View article titled, Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor
Open the PDF for Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor in another window